Labcorp Appoints Victor Bulto to Board of Directors

By Ahmed Jameison • Monday, November 24 12:02 • Permanent Link

Labcorp (NYSE: LH) has appointed Victor Bulto, President, U.S. of Novartis, to its Board of Directors, effective December 1, 2025. Bulto brings 25 years of healthcare experience and is currently responsible for Novartis' U.S. business, overseeing key therapeutic areas such as oncology, immunology, neuroscience, and cardiovascular-renal-metabolic, with a $20+ billion operation.

Labcorp's Chairman and Chief Executive Officer, Adam Schechter, expressed that Bulto's appointment underscores Labcorp’s focus on long-term growth through innovation and global healthcare leadership. Bulto's expertise is expected to be invaluable in advancing Labcorp's strategic priorities and focusing on innovating through science and technology to deliver greater value for customers and shareholders.

Labcorp is a global leader of innovative and comprehensive laboratory services, with nearly 70,000 employees serving clients in approximately 100 countries. The company provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA and performs more than 700 million tests annually for patients around the world.

The press release did not include specific financial metrics or performance data for Labcorp. The market has reacted to these announcements by moving the company's shares 1.59% to a price of $265.64. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.